<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>379</serviceExecutionTime><Drug id="4446"><DrugName>SQ-32709</DrugName><DrugSynonyms><Name><Value>SQ-32709</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>372-97-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="33" type="ciIndication"><TargetEntity id="I70" type="ICD10"></TargetEntity><TargetEntity id="440" type="ICD9"></TargetEntity><TargetEntity id="D050197" type="MeSH"></TargetEntity><TargetEntity id="-848966698" type="omicsDisease"></TargetEntity><TargetEntity id="208" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="352" type="Action"><TargetEntity id="493" type="Mechanism">Squalene Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01760" type="ciTarget"><TargetEntity id="106031814622223" type="siTarget">Squalene synthase</TargetEntity><TargetEntity id="-1693240406" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication><Indication id="33">Atherosclerosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="352">Squalene synthetase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2667">Antiarteriosclerotic</Action><Action id="71">Antihypercholesterolemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-02T10:31:33.000Z</LastModificationDate><ChangeDateLast>2003-05-23T11:05:05.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Bristol-Myers Squibb has discontinued development of &lt;ulink linkID="4446" linkType="Drug"&gt;SQ-32709&lt;/ulink&gt;, a squalene synthetase inhibitor, which had potential for the treatment of hyperlipidemia and atherosclerosis [&lt;ulink linkID="190118" linkType="reference"&gt;190118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Squalene synthetase is the enzyme which catalyses a key branch-point reaction in the cholesterol biosynthetic pathway. It has therefore been rationalized that selective inhibition of squalene synthetase should avoid any problems that may be associated with inhibition at earlier steps in the pathway e.g. a decrease in the level of intermediates required for other (non-cholesterol) products of this pathway. Bristol Myers Squibb's designs for its inhibitors were based on the knowledge that the diphosphate group in the natural substrate, farnesyl diphosphate (FPP) is essential for enzyme- substrate binding. Because diphosphate is unstable, a series of analogues were prepared in which, for example, a (phosphinylmethyl)phosphonate or a phosphinylformate moiety substitute for the natural diphosphate to produce a stable inhibitor.&lt;/para&gt;&lt;para&gt;Most of the information on Squibb's work in this area comes from the patent literature. In addition to claiming novel squalene synthetase inhibitors, the company has also filed patents claiming combination therapy using synthetase inhibitors and an HMG-CoA reductase inhibitor and/or a variety of other antihyperlipidaemic agents. Other companies active in the R&amp;amp;D of squalene synthetase inhibitors include Merck and Glaxo.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="33">Atherosclerosis</Indication><Source id="190118" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><Source id="190118" type="CORPORATE"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-01760"><Name>Squalene synthetase</Name><SwissprotNumbers><Swissprot>O74165</Swissprot><Swissprot>P29704</Swissprot><Swissprot>P36596</Swissprot><Swissprot>P37268</Swissprot><Swissprot>P53798</Swissprot><Swissprot>P53799</Swissprot><Swissprot>P53800</Swissprot><Swissprot>P78589</Swissprot><Swissprot>Q02769</Swissprot><Swissprot>Q752X9</Swissprot><Swissprot>Q7S4Z6</Swissprot><Swissprot>Q92459</Swissprot><Swissprot>Q9HGZ6</Swissprot><Swissprot>Q9Y753</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(=CCC/C(=C/CC/C(=C/COCP(=O)(O)OP(=O)(O)O)/C)/C)C</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1710674" number="EP-00401705" title="Use of an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease."></PatentFamily><PatentFamily id="1793734" number="GB-02227662" title="Lowering serum cholesterol using a HMG CoA reductase inhibitor and a squalene   synthetase inhibitor."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>